Cargando…
Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Background. Contrast-induced nephropathy (CIN) limits the outcome of percutaneous coronary intervention (PCI). Objective. To investigate whether pretreatment with Compound Danshen Dripping Pills (CDDP) will decrease the incidence of CIN after PCI. Methods. A total of 229 patients with acute coronary...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216665/ https://www.ncbi.nlm.nih.gov/pubmed/25386219 http://dx.doi.org/10.1155/2014/256268 |
_version_ | 1782342294449422336 |
---|---|
author | Yang, Rong Chang, Liang Guo, Bing-yan Wang, Yan-wei Wang, Ya-ling Jin, Xin Liu, Su-yun Li, Yong-jun |
author_facet | Yang, Rong Chang, Liang Guo, Bing-yan Wang, Yan-wei Wang, Ya-ling Jin, Xin Liu, Su-yun Li, Yong-jun |
author_sort | Yang, Rong |
collection | PubMed |
description | Background. Contrast-induced nephropathy (CIN) limits the outcome of percutaneous coronary intervention (PCI). Objective. To investigate whether pretreatment with Compound Danshen Dripping Pills (CDDP) will decrease the incidence of CIN after PCI. Methods. A total of 229 patients with acute coronary syndrome (ACS) undergoing PCI were divided into the control group (n = 114) and the CDDP (containing salvia miltiorrhiza and sanqi) group (n = 115; given 20 CDDP pills, three times daily before PCI). Serum creatinine, creatinine clearance (CrCl), high-sensitivity C-reactive protein (hsCRP), P-selectin, and intercellular adhesion molecule-1 (ICAM-1) were measured at admission and 24 and 48 h after PCI. Results. CrCl decreased after PCI but recovered after 48 h. In the CDDP group, CrCl recovered more rapidly (P < 0.05). The procedure increased the hsCRP, P-selectin, and ICAM-1 levels, but these levels were less in the CDDP group (P < 0.05). Conclusions. Pretreatment with CDDP can decrease the occurrence of CIN in patients undergoing PCI, suggesting that the early use of CDDP is an appropriate adjuvant pharmacological therapy before PCI. |
format | Online Article Text |
id | pubmed-4216665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-42166652014-11-10 Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Yang, Rong Chang, Liang Guo, Bing-yan Wang, Yan-wei Wang, Ya-ling Jin, Xin Liu, Su-yun Li, Yong-jun Evid Based Complement Alternat Med Research Article Background. Contrast-induced nephropathy (CIN) limits the outcome of percutaneous coronary intervention (PCI). Objective. To investigate whether pretreatment with Compound Danshen Dripping Pills (CDDP) will decrease the incidence of CIN after PCI. Methods. A total of 229 patients with acute coronary syndrome (ACS) undergoing PCI were divided into the control group (n = 114) and the CDDP (containing salvia miltiorrhiza and sanqi) group (n = 115; given 20 CDDP pills, three times daily before PCI). Serum creatinine, creatinine clearance (CrCl), high-sensitivity C-reactive protein (hsCRP), P-selectin, and intercellular adhesion molecule-1 (ICAM-1) were measured at admission and 24 and 48 h after PCI. Results. CrCl decreased after PCI but recovered after 48 h. In the CDDP group, CrCl recovered more rapidly (P < 0.05). The procedure increased the hsCRP, P-selectin, and ICAM-1 levels, but these levels were less in the CDDP group (P < 0.05). Conclusions. Pretreatment with CDDP can decrease the occurrence of CIN in patients undergoing PCI, suggesting that the early use of CDDP is an appropriate adjuvant pharmacological therapy before PCI. Hindawi Publishing Corporation 2014 2014-10-16 /pmc/articles/PMC4216665/ /pubmed/25386219 http://dx.doi.org/10.1155/2014/256268 Text en Copyright © 2014 Rong Yang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yang, Rong Chang, Liang Guo, Bing-yan Wang, Yan-wei Wang, Ya-ling Jin, Xin Liu, Su-yun Li, Yong-jun Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title | Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title_full | Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title_fullStr | Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title_full_unstemmed | Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title_short | Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
title_sort | compound danshen dripping pill pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216665/ https://www.ncbi.nlm.nih.gov/pubmed/25386219 http://dx.doi.org/10.1155/2014/256268 |
work_keys_str_mv | AT yangrong compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT changliang compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT guobingyan compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT wangyanwei compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT wangyaling compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT jinxin compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT liusuyun compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention AT liyongjun compounddanshendrippingpillpretreatmenttopreventcontrastinducednephropathyinpatientswithacutecoronarysyndromeundergoingpercutaneouscoronaryintervention |